Bank of New York Mellon
TSRX

Bank of New York Mellon’s TRIUS THERAPEUTICS INC COM STK (DE) TSRX Stock Holding History

Bank of New York Mellon’s Portfolio TSRX Stock Details TSRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-227,272
Closed -$1.84M – 4248
2013
Q2 		$1.84M Buy
+227,272
New +$1.68M ﹤0.01% 2839

Other funds holding TSRX

PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 27.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
FCH
Freestone Capital Holdings Seattle, Washington $3.86B AUM 26.3% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $1.15B AUM 24.81% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Bank of New York Mellon's TSRX Position: Q3 2013 in Review

Bank of New York Mellon sold out of TRIUS THERAPEUTICS INC COM STK (DE) (TSRX) in Q3 2013, closing a stake of 227,272 shares — an estimated $1.84M sold.

Bank of New York Mellon first reported a position in TSRX in Q2 2013 and held it in 1 quarter. The position peaked at $1.84M in Q2 2013. 7 funds tracked by Wall St. Rank hold TSRX as of Q3 2013.

  • Bank of New York Mellon reported no remaining TRIUS THERAPEUTICS INC COM STK (DE) position as of Q3 2013 after selling out during the quarter.
  • Bank of New York Mellon sold 227,272 TRIUS THERAPEUTICS INC COM STK (DE) shares in Q3 2013, an estimated $1.84M.
  • Bank of New York Mellon first reported a position in TRIUS THERAPEUTICS INC COM STK (DE) in Q2 2013 and held it in 1 quarter.
  • Bank of New York Mellon's TRIUS THERAPEUTICS INC COM STK (DE) position peaked at $1.84M in Q2 2013.
  • 7 funds tracked by Wall St. Rank held TRIUS THERAPEUTICS INC COM STK (DE) as of Q3 2013.

Based on Bank of New York Mellon's 13F filing for Q3 2013, filed 13 Nov 2013.